Serum thyroxine and age - rather than thyroid volume and serum TSH - are determinants of the thyroid radioiodine uptake in patients with nodular goiter

S J Bonnema; S Fast; V E Nielsen; H Boel-Jørgensen; P Grupe; P B Andersen; L Hegedüs

doi:10.3275/7260

Serum thyroxine and age - rather than thyroid volume and serum TSH - are determinants of the thyroid radioiodine uptake in patients with nodular goiter

S J Bonnema, S Fast, V E Nielsen, H Boel-Jørgensen, P Grupe, P B Andersen, L Hegedüs

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Background: 131I therapy is widely used for treatment of non-toxic goiters. A limitation for this treatment is a low thyroid radioiodine uptake (RAIU), often encountered in these patients. Aim: To estimate the impact of various factors on the thyroid RAIU. Methods: We examined prospectively 170 patients (146 females; age range: 22-87 yrs.) with nodular goiter (median 64 ml, range: 20-464 ml) selected for 131I therapy. Serum TSH was sub-normal in 42.4%. None were treated with anti-thyroid drugs. The thyroid RAIU was determined at 24h and 96h. The goiter volume was measured by ultrasound (n=127), or by magnetic resonance imaging (n=43). Results: The 24h and the 96h RAIU were 34.2±9.8(SD)% (range:11.4-66.0%) and 34.0±10.0% (range:10.5-60.9%), respectively. Sixty-one patients had a 24h RAIU

Original language	English
Journal	Journal of Endocrinological Investigation
Volume	34
Issue number	3
Pages (from-to)	52-7
Number of pages	6
ISSN	1720-8386
DOIs	https://doi.org/10.3275/7260
Publication status	Published - 2011

Documents & Links

10.3275/7260

Cite this

@article{fdd1552bc63c4ec7b78ed56970227cac,

title = "Serum thyroxine and age - rather than thyroid volume and serum TSH - are determinants of the thyroid radioiodine uptake in patients with nodular goiter",

abstract = "Background: 131I therapy is widely used for treatment of non-toxic goiters. A limitation for this treatment is a low thyroid radioiodine uptake (RAIU), often encountered in these patients. Aim: To estimate the impact of various factors on the thyroid RAIU. Methods: We examined prospectively 170 patients (146 females; age range: 22-87 yrs.) with nodular goiter (median 64 ml, range: 20-464 ml) selected for 131I therapy. Serum TSH was sub-normal in 42.4%. None were treated with anti-thyroid drugs. The thyroid RAIU was determined at 24h and 96h. The goiter volume was measured by ultrasound (n=127), or by magnetic resonance imaging (n=43). Results: The 24h and the 96h RAIU were 34.2±9.8(SD)% (range:11.4-66.0%) and 34.0±10.0% (range:10.5-60.9%), respectively. Sixty-one patients had a 24h RAIU ",

author = "Bonnema, {S J} and S Fast and Nielsen, {V E} and H Boel-J{\o}rgensen and P Grupe and Andersen, {P B} and L Heged{\"u}s",

year = "2011",

doi = "10.3275/7260",

language = "English",

volume = "34",

pages = "52--7",

journal = "Journal of Endocrinological Investigation",

issn = "1720-8386",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Serum thyroxine and age - rather than thyroid volume and serum TSH - are determinants of the thyroid radioiodine uptake in patients with nodular goiter

AU - Bonnema, S J

AU - Fast, S

AU - Nielsen, V E

AU - Boel-Jørgensen, H

AU - Grupe, P

AU - Andersen, P B

AU - Hegedüs, L

PY - 2011

Y1 - 2011

N2 - Background: 131I therapy is widely used for treatment of non-toxic goiters. A limitation for this treatment is a low thyroid radioiodine uptake (RAIU), often encountered in these patients. Aim: To estimate the impact of various factors on the thyroid RAIU. Methods: We examined prospectively 170 patients (146 females; age range: 22-87 yrs.) with nodular goiter (median 64 ml, range: 20-464 ml) selected for 131I therapy. Serum TSH was sub-normal in 42.4%. None were treated with anti-thyroid drugs. The thyroid RAIU was determined at 24h and 96h. The goiter volume was measured by ultrasound (n=127), or by magnetic resonance imaging (n=43). Results: The 24h and the 96h RAIU were 34.2±9.8(SD)% (range:11.4-66.0%) and 34.0±10.0% (range:10.5-60.9%), respectively. Sixty-one patients had a 24h RAIU

AB - Background: 131I therapy is widely used for treatment of non-toxic goiters. A limitation for this treatment is a low thyroid radioiodine uptake (RAIU), often encountered in these patients. Aim: To estimate the impact of various factors on the thyroid RAIU. Methods: We examined prospectively 170 patients (146 females; age range: 22-87 yrs.) with nodular goiter (median 64 ml, range: 20-464 ml) selected for 131I therapy. Serum TSH was sub-normal in 42.4%. None were treated with anti-thyroid drugs. The thyroid RAIU was determined at 24h and 96h. The goiter volume was measured by ultrasound (n=127), or by magnetic resonance imaging (n=43). Results: The 24h and the 96h RAIU were 34.2±9.8(SD)% (range:11.4-66.0%) and 34.0±10.0% (range:10.5-60.9%), respectively. Sixty-one patients had a 24h RAIU

U2 - 10.3275/7260

DO - 10.3275/7260

M3 - Journal article

C2 - 20834199

SN - 1720-8386

VL - 34

SP - 52

EP - 57

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

IS - 3

ER -

Serum thyroxine and age - rather than thyroid volume and serum TSH - are determinants of the thyroid radioiodine uptake in patients with nodular goiter

Abstract

Documents & Links

Fingerprint

Cite this